LifeCycle Pharma Increases Share Capital by 334,469 Shares as a Consequence of the Exercise of Employee Warrants

Company Announcement no. 09/2008
To: OMX Nordic Exchange Copenhagen		      Hørsholm, Denmark, March 14, 2008

 
LifeCycle Pharma Increases Share Capital by 334,469 Shares as a Consequence of
the Exercise of Employee Warrants 

Summary: LifeCycle Pharma increases its share capital by nom. 334,469 shares as
a consequence of the exercise of warrants. 

 LifeCycle Pharma A/S (OMX: LCP) has decided to increase its share capital by
nom. 334,469 shares as a consequence of the exercise of warrants. The increase
is effected without any pre-emption rights for the existing shareholders of the
company or others. 

The shares are subscribed in cash as follows: (1) Nom. 80,000 shares are
subscribed against payment of DKK 2.5 per share of nom. DKK 1. (2) Nom. 250,636
shares are subscribed against payment of DKK 7.885 per share of nom. DKK 1. (3)
Nom. 3,883 shares are subscribed against payment of DKK 22.3 per share of nom.
DKK 1. Gross proceeds to the company are DKK 2,261,740. The increase
corresponds to approx. 1.04 % of the company's share capital after the
increase. The new shares are ordinary bearer shares without any special rights
and are freely transferable negotiable instruments. The new shares shall give
rights to dividends and other rights in relation to the company from the date
of the registration of the capital increase with the Commerce and Companies
Agency. The new shares will be listed on the OMX after registration with the
said agency. The company's current share capital amounts to DKK 31,770,705
shares and will after the capital increase be DKK 32,105,174. The capital
increase is expected to be finalized shortly. 

About LifeCycle Pharma A/S (“LCP”)
LCP is an emerging specialty pharmaceutical company that, through innovative
technologies, is able to rapidly develop a portfolio of differentiated products
to meet the unique needs of key therapeutic markets and patient populations.
This includes products for immunosuppression, specifically organ
transplantation, and to combat certain cardiovascular diseases. By using its
unique and patented delivery technology, MeltDose®, LCP is able to develop
drugs with enhanced absorption and thereby increased bioavailability. LCP has a
cholesterol lowering product, FenoglideTM, currently on the U.S. market and a
diversified near- and medium-term pipeline, including five product candidates
in clinical trials and three in preclinical stages of development. LCP is
listed on the OMX Nordic Exchange Copenhagen under the trading symbol (OMX:
LCP). 

For further information, please visit www.lcpharma.com.

For further information please contact LifeCycle Pharma A/S: 
Flemming Ornskov, MD
President and CEO  
+45 2420 0368; FO@lcpharma.com 
or:
Hans Christian Teisen 
Senior Vice President  & CFO
+45 20 30 69 85;  E-mail: hct@lcpharma.com